Values as of: 2024-09-22
COMMON STOCK | Medical Distribution |
Last Closing
USD 228.11Change
0.00 (0.00)%Market Cap
USD 44.41BVolume
6.65MAnalyst Target
USD 128.75Verdict
Verdict
Cencora, Inc. sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers. This segment also distributes plasma and other blood products, injectable pharmaceuticals, vaccines, and other specialty products; and provides other services to physicians who specialize in various disease states, such as oncology, as well as to other healthcare providers, including hospitals and dialysis clinics. Its International Healthcare Solutions segment offers international pharmaceutical wholesale and related service, and global commercialization services; distributes pharmaceuticals, other healthcare products, and related services to pharmacies, doctors, health centers, and hospitals primarily in Europe; and provides specialty transportation and logistics services for the biopharmaceutical industry. The company was formerly known as AmerisourceBergen Corporation and changed its name to Cencora, Inc. in August 2023. Cencora, Inc. was incorporated in 2001 and is headquartered in Conshohocken, Pennsylvania.
Company Website : https://www.cencora.com
Currency: USD
Country : USA
| Symbol | Name | Price(Change) | Market Cap |
|---|---|---|---|
| CAH | Cardinal Health Inc |
N/A |
USD 26.96B |
| MCK | McKesson Corporation |
N/A |
N/A |
| OMI | Owens & Minor Inc |
N/A |
N/A |
| NVG | Nuveen AMT Free Municipal Cred.. |
N/A |
N/A |
| Symbol | Name | Weight | Mer | Price(Change) | Market Cap |
|---|---|---|---|---|---|
| CUDV:CA | CI U.S. Minimum Downside .. | 4.32 % | 0.00 % |
N/A |
CAD 8.37M |
| SAMT | The Advisorsa Inner C.. | 3.72 % | 0.00 % |
N/A |
USD 0.07B |
| RUD:CA | RBC Quant US Dividend Lea.. | 3.08 % | 0.43 % |
N/A |
CAD 0.60B |
| IQSA:F | Invesco Markets II PLC - .. | 1.48 % | 0.00 % |
N/A |
N/A |
| IQSE:F | Invesco Markets II PLC - .. | 1.48 % | 0.00 % |
N/A |
N/A |
| FMDE | Fidelity Covington Trust | 0.82 % | 0.00 % |
N/A |
USD 1.58B |
| IWP | iShares Russell Mid-Cap G.. | 0.00 % | 0.24 % |
N/A |
USD 14.62B |
| PGAL | 0.00 % | 0.57 % |
N/A |
N/A | |
| RUD-U:CA | RBC Quant U.S. Dividend L.. | 0.00 % | 0.00 % |
N/A |
N/A |
| CD47:XETRA | 0.00 % | 0.00 % |
N/A |
N/A | |
| BLOV:CA | Brompton North American L.. | 0.00 % | 0.00 % |
N/A |
CAD 0.01B |
| BMED | BlackRock Future Health E.. | 0.00 % | 0.00 % |
N/A |
USD 4.21M |
| CBUF:XETRA | iShares MSCI World Health.. | 0.00 % | 0.00 % |
N/A |
USD 1.13B |
| Market Performance vs. Industry/Classification (Medical Distribution) | Market Performance vs. Exchange | ||||||
| Value | Sector Median | Percentile Rank | Grade | Market Median | Percentile Rank | Grade | |
| YTD | |||||||
| Capital Gain | 11.07% | 80% | B- | 61% | D- | ||
| Dividend Return | 0.74% | 50% | F | 17% | F | ||
| Total Return | 11.81% | 60% | D- | 56% | F | ||
| Trailing 12 Months | |||||||
| Capital Gain | 22.67% | 60% | D- | 67% | D+ | ||
| Dividend Return | 1.10% | 50% | F | 14% | F | ||
| Total Return | 23.77% | 60% | D- | 62% | D | ||
| Trailing 5 Years | |||||||
| Capital Gain | 92.89% | 40% | F | 84% | B | ||
| Dividend Return | 13.22% | 60% | D- | 49% | F | ||
| Total Return | 106.11% | 40% | F | 85% | B | ||
| Average Annual (5 Year Horizon) | |||||||
| Capital Gain | 17.99% | 40% | F | 81% | B- | ||
| Dividend Return | 20.24% | 40% | F | 82% | B | ||
| Total Return | 2.26% | 60% | D- | 49% | F | ||
| Risk Return Profile | |||||||
| Volatility (Standard Deviation) | 15.82% | 80% | B- | 62% | D | ||
| Risk Adjusted Return | 127.95% | 80% | B- | 99% | N/A | ||
| Market Capitalization | 44.41B | 100% | F | 95% | A | ||
| Target Price Action | Rating Action | Analyst | Rating | Price | Date |
|---|
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.
The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.
The stock is trading low compared to its peers on a price to earning basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.
The company had positive total cash flow in the most recent four quarters.
The company had positive total free cash flow in the most recent four quarters.
The stock is trading low compared to its peers on a price to free cash flow basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.
This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.
This stock has shown top quartile dividend growth in the previous 5 years compared to its sector
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
The stock is trading high compared to its peers median on a price to book value basis.
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
